The use of drugs in renal failure.
We have tried to emphasize specific variables that impact upon the use of drugs in the patient with renal disease. These variables are complex, often interrelated, and if neglected by the physician will surely lead to unwarranted drug reactions and serious harm to the patient. We have purposely limited the tables of "Selected Pharmacologic Agents" to a few prototypic drugs from each class, emphasizing the newer agents recently introduced in clinical medicine. We strongly recommend that as new drugs are used, the original literature be consulted for verification.
Reed
W E
WE
Sabatini
S
S
D000700:Analgesics / Q000378:metabolism; D000818:Animals; D000890:Anti-Infective Agents / Q000378:metabolism; D000970:Antineoplastic Agents / Q000378:metabolism; D001693:Biological Transport, Active; D002317:Cardiovascular Agents / Q000378:metabolism; D002491:Central Nervous System Agents / Q000378:metabolism; D005765:Gastrointestinal Agents / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000378:metabolism; D007668:Kidney / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D006435:Renal Dialysis
D000700:Analgesics; D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D002317:Cardiovascular Agents; D002491:Central Nervous System Agents; D005765:Gastrointestinal Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents